4-羟基磷酸苯酯 | 33795-18-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 4-羟基磷酸苯酯
• 中文别名: (4-羟基苯基)膦酸
• 英文名称: (4-Hydroxy-phenyl)-phosphonsaeure
• 英文别名: (4-Hydroxyphenyl)phosphonic acid
• CAS: 33795-18-5
• 化学式: C₆H₇O₄P
• mdl: MFCD01112120
• 分子量: 174.093
• InChiKey: YIDVLWDHYNWHMH-UHFFFAOYSA-N

物化性质

• 熔点：
  168.0 to 172.0 °C
• 沸点：
  439.9±47.0 °C(Predicted)
• 密度：
  1.60±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2931900090

反应信息

• 作为产物：
  描述：

  (4-氨基苯基)磷酸 在 盐酸 、 亚硝酸乙酯 作用下， 生成 4-羟基磷酸苯酯
  参考文献：
  名称：

  Synthesis of Phosphanilic Acid and Related Compounds¹

  摘要：

  DOI：

  10.1021/ja01123a049

文献信息

• Inhibitors of GSK-3 and crystal structures of GSK-3 protein and protein complexes
  申请人：——

  公开号：US20030125332A1

  公开（公告）日：2003-07-03

  The present invention relates to inhibitors of GSK-3 and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. In addition, the invention relates to molecules or molecular complexes which comprise binding pockets of GSK-3&bgr; or its homologues. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. The invention relates to methods of using the structure coordinates to screen for and design compounds that bind to GSK-3&bgr; protein or homologues thereof. The invention also relates to crystallizable compositions and crystals comprising GSK-3&bgr; protein or GSK-3&bgr; protein complexes.

  本发明涉及GSK-3的抑制剂及制备这些抑制剂的方法。本发明还提供了包含这些抑制剂的药物组合物，并提供了利用这些组合物在治疗和预防各种疾病，如糖尿病和阿尔茨海默病等方面的方法。此外，本发明涉及包含GSK-3β或其同源物的结合口袋的分子或分子复合物。本发明涉及一种计算机，其包括一个数据存储介质，编码有这些结合口袋的结构坐标。本发明还涉及利用这些结构坐标来解决同源蛋白质或蛋白质复合物的结构的方法。本发明涉及利用这些结构坐标来筛选和设计能够结合到GSK-3β蛋白或其同源物的化合物的方法。本发明还涉及包含GSK-3β蛋白或GSK-3β蛋白复合物的可结晶组合物和晶体。
• Competitive immunoassay
  申请人：Beechem Joseph

  公开号：US20060160068A1

  公开（公告）日：2006-07-20

  The present invention provides ligand-detection reagents, ligand analogs and methods for determining the presence of a ligand in a sample. The ligand-detection reagent comprises a ligand-binding antibody and a ligand analog to form an antibody-ligand analog complex wherein the ligand analog is covalently bonded to a reporter molecule. This complex may additionally comprise a labeling protein non-covalently bonded to the antibody to form a ternary complex wherein the labeling protein comprises a monovalent antibody fragment or a non-antibody protein that is covalently bonded to a label moiety. The reporter molecule is either quenched by the ligand-binding antibody or by the label moiety of the labeling protein, depending on the reporter molecule and the ligand-binding antibody, wherein the amount of quenching is directly related to the amount of ligand present in the sample. Alternatively, the ligand analog is fluorogenic wherein the ligand analog is essentially non-fluorescent in solution but when bound by the ligand-binding antibody the detectable signal increases. In this instance a decrease in signal, as opposed to the relieving of quenching, is measured for the presence of a target ligand.

  本发明提供了配体检测试剂、配体类似物和用于确定样品中配体存在的方法。该配体检测试剂包括一个配体结合抗体和一个配体类似物，形成一个抗体-配体类似物复合物，其中配体类似物与一个报告分子共价结合。该复合物还可以包括一个标记蛋白，非共价结合于抗体上，形成一个三元复合物，其中标记蛋白包括单价抗体片段或共价结合于标记基团的非抗体蛋白。报告分子可以被配体结合抗体或标记蛋白的标记基团熄灭，具体取决于报告分子和配体结合抗体，其中熄灭的程度与样品中配体的数量直接相关。或者，配体类似物是荧光原性的，其中配体类似物在溶液中基本上不发荧光，但当被配体结合抗体结合时，可检测的信号增加。在这种情况下，对于目标配体的存在，测量的是信号的降低，而不是熄灭的缓解。
• Process for Producing Polyester, Polyester Produced Using Said Process, and Polyester Molded Product
  申请人：Kageyama Katsuhiko

  公开号：US20080249280A1

  公开（公告）日：2008-10-09

  This invention provides a polyester and a polyester molded product, which, while maintaining color tone, transparency, and thermal stability, can realize a high polycondensation rate, are less likely to cause the production of polycondensation catalyst-derived undesired materials, and can simultaneously meet both quality and cost effectiveness requirements, which can exhibit the characteristic features, for example, in the fields of ultrafine fibers, high transparent films for optical use, or ultrahigh transparent molded products. These advantages can be realized by using, in the production of a polyester in the presence of an aluminum compound-containing polyester polycondensation catalyst, an aluminum compound having an absorbance of not more than 0.0132 as measured in the form of an aqueous aluminum compound solution, prepared by dissolving the aluminum compound in pure water to give a concentration of 2.7 g/liter in terms of the amount of aluminum element, under conditions of cell length 1 cm and wavelength 680 nm.

  本发明提供了一种聚酯和聚酯成型产品，可以在保持色调、透明度和热稳定性的同时，实现高聚酯化速率，不太可能引起聚酯化催化剂来源的不良材料的生产，并且可以同时满足质量和成本效益的要求，这些优点可以在超细纤维、用于光学的高透明薄膜或超高透明成型产品等领域展现出特征性能。通过在含有铝化合物聚酯聚合催化剂的聚酯生产中使用具有吸光度不超过0.0132的铝化合物，可以实现这些优点。该吸光度是在细胞长度为1厘米，波长为680纳米的条件下，将铝化合物溶解在纯水中以给定铝元素量浓度为2.7克/升形成的水溶性铝化合物溶液中测量得出的。
• Inhibitors of GSK-3 and crystal structures of GSK-3beta protein and protein complexes
  申请人：ter Haar Ernst

  公开号：US20080262205A1

  公开（公告）日：2008-10-23

  The present invention relates to inhibitors of GSK-3 and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. In addition, the invention relates to molecules or molecular complexes which comprise binding pockets of GSK-3β or its homologues. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. The invention relates to methods of using the structure coordinates to screen for and design compounds that bind to GSK-3β protein or homologues thereof. The invention also relates to crystallizable compositions and crystals comprising GSK-3β protein or GSK-3β protein complexes.

  本发明涉及GSK-3抑制剂及其制备方法。本发明还提供了包含该抑制剂的药物组合物以及将这些组合物用于治疗和预防各种疾病，如糖尿病和阿尔茨海默病的方法。此外，本发明涉及包含GSK-3β或其同源物的结合口袋的分子或分子复合物。本发明涉及一台计算机，该计算机包括编码有这些结合口袋的结构坐标的数据存储介质。本发明还涉及使用结构坐标来解决同源蛋白质或蛋白质复合物的结构的方法。本发明涉及使用结构坐标来筛选和设计与GSK-3β蛋白质或其同源物结合的化合物的方法。本发明还涉及包含GSK-3β蛋白质或GSK-3β蛋白质复合物的可结晶化组合物和晶体。
• PROCESSES FOR THE PREPARATION OF CALIXARENE DERIVATIVES
  申请人：Raston Colin L.

  公开号：US20100185022A1

  公开（公告）日：2010-07-22

  A method for the preparation of calix[n]arene derivatives, in particular phosphonated calix[n]arenes. The present invention also relates to nano-structures of phosphonated calix[n]arenes.

  一种制备杯[n]芳烃衍生物的方法，特别是磷酸衍生的杯[n]芳烃。本发明还涉及磷酸衍生的杯[n]芳烃的纳米结构。

表征谱图